Evidence map›Paper›PMID 38766059›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Association of immunoglobulin E levels with glioma risk and survival.

Geno Guerra, Taishi Nakase, Linda Kachuri, Lucie McCoy, Helen M Hansen, Terri Rice, Joseph L Wiemels, John K Wiencke, Annette M Molinaro, Margaret Wrensch and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Geno GuerraDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9870-9998
Taishi NakaseDepartment of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-3078-098X
Linda KachuriDepartment of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-3226-4727
Lucie McCoyDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Helen M HansenDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Terri RiceDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Joseph L WiemelsCenter for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0003-4838-9951
John K WienckeDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Annette M MolinaroDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Margaret WrenschDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Stephen S FrancisDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Susan M Chang · 2002 to 2026
$57.4M
GENETIC EPIDEMIOLOGY OF MALIGNANT GLIOMAR01CA052689 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K., WRENSCH, MARGARET R. · 1991 to 2015
$20.5M
International Case Control Study of Malignant GliomaR01CA139020 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BONDY, MELISSA L. · 2010 to 2015
$16.0M
Discovering Infection-mediated Pathways of Glioma Etiology and Prognosis by Leveraging Multiplex Serology and ImmunogenomicsR01CA266676 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FRANCIS, STEPHEN STARKO · 2022 to 2025
$2.6M
Biomarkers of survival in glioma epidemiologyR01CA126831 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K. · 2008 to 2013
$2.5M
Comprehensive Investigation of Multiple Myeloma Genetic Susceptibility in African AmericansR00CA246076 · NCI · STANFORD UNIVERSITY · PI KACHURI, MIRLINDA · 2022 to 2024
$747k
NCCDPHP CDC HHS NU58DP006344NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS P50 CA097257NCI NIH HHS R00 CA246076NCI NIH HHS R01 CA052689NCI NIH HHS R01 CA126831NCI NIH HHS R01 CA139020NCI NIH HHS R01 CA266676NCRR NIH HHS UL1 RR024131
6 · The paper itself

Abstract

Background: Previous epidemiologic studies have reported an association of serum immunoglobulin E (IgE) levels with reduced glioma risk, but the association between IgE and glioma prognosis has not been characterized. This study aimed to examine how sex, tumor subtype, and IgE class modulate the association of serum IgE levels with glioma risk and survival. Methods: We conducted a case-control study using participants from the University of California, San Francisco Adult Glioma Study (1997-2010). Serum IgE levels for total, respiratory and food allergy were measured in adults diagnosed with glioma (n=1319) and cancer-free controls (n=1139) matched based on age, sex, and race and ethnicity. Logistic regression was adjusted for patient demographics to assess the association between IgE levels and glioma risk. Multivariable Cox regression adjusted for patient-specific and tumor-specific factors compared survival between the elevated and normal IgE groups. All statistical tests were 2-sided. Results: Elevated total IgE was associated with reduced risk of IDH-wildtype (RR=0.78, 95% CI: 0.71-0.86) and IDH-mutant glioma (RR=0.73, 95% CI: 0.63-0.85). In multivariable Cox regression, positive respiratory IgE was associated with improved survival for IDH-wildtype glioma (RR=0.79, 95% CI: 0.67-0.93). The reduction in mortality risk was significant in females only (RR=0.75, 95% CI: 0.57-0.98) with an improvement in median survival of 6.9 months (P<.001). Conclusion: Elevated serum IgE was associated with improved prognosis for IDH-wildtype glioma, with a more pronounced protective effect in females than males, which has implications for the future study of IgE-based immunotherapies for glioma.

Identifiers

PMID38766059
PMCPMC11100947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.